AbbVie Inc. $ABBV Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,479,061 shares of the company’s stock after purchasing an additional 24,183 shares during the quarter. AbbVie accounts for about 1.1% of Fifth Third Bancorp’s investment portfolio, making the stock its 16th largest holding. Fifth Third Bancorp owned about 0.08% of AbbVie worth $342,462,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ellenbecker Investment Group lifted its holdings in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its position in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares during the period. Centennial Wealth Advisory LLC increased its position in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after buying an additional 45 shares during the period. Finally, Willner & Heller LLC lifted its stake in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research note on Tuesday, November 4th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Piper Sandler restated an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Finally, UBS Group reduced their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Up 1.8%

Shares of AbbVie stock opened at $231.57 on Monday. The business has a fifty day simple moving average of $223.56 and a 200-day simple moving average of $221.07. The firm has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.